The Judicial Panel on Multidistrict Litigation will meet to discuss centralizing dozens of Actos lawsuits to a single courtroom. About 54 lawsuits against Takeda Pharmaceuticals America Inc. allege the company failed to warn consumers its anti-diabetes drug Actos could increase the risks of bladder cancer after taking the drug for at least one year.
Plaintiffs claim that centralizing the lawsuits to one district judge would be the most efficient way to handle common issues among the cases. A judicial panel will meet in December to discuss the proposal.
France and Germany suspended the sale of Actos in June 2011 after research suggested the drug increases the risks of developing bladder cancer in patients who use it for at least one year. The Food and Drug Administration has issued a warning on the drug, but has not announced any plans for an Actos recall.